Newsletter | August 19, 2026

08.19.26 -- Unlocking Gentler, Cost-Efficient TIL Therapy For Cold Tumors

SPONSOR

Join us on August 25th to learn how to optimize Parkinson's disease clinical trials. Experts from Dr. Vince Clinical Research and the Davis Phinney Foundation will discuss trial design, endpoint selection, patient-centered research, and operational challenges for symptomatic and disease-modifying therapies. Attendees will gain practical strategies, real-world case studies, and insights to support successful CNS drug development from early-phase studies through NDA submission.

TRIAL MANAGEMENT

Unlocking Gentler, Cost-Efficient TIL Therapy For Cold Tumors

CuraCell Head of Clinical Operations Torbjörn Ström discusses, in the context of CC-38 and CytoPLY-derived tumor-infiltrating lymphocytes (TILs), the utility of named-patient experience, dosing and preconditioning, and T-cell therapy capabilities in cold solid tumors.

Global Trials, Zero Delays: Rethinking Clinical Logistics

This comprehensive guide provides practical insights and best practices for ensuring the timely, secure, and reliable delivery of clinical trial materials worldwide.

Planning Your First-In-Human Trial?

Learn the critical strategies for designing safer, regulator-ready first-in-human trials while reducing risk, avoiding delays, and accelerating your path to clinical development.

Busy Quarter For Gene, Cell, RNA Therapies

Explore how Q2 brought renewed momentum for gene, cell, and RNA therapies and grew confidence in the future of advanced medicine with rising approvals, expanding pipelines, and increased investment.

Improving Clinical Trial Access To Meet Regulatory And Patient Needs

Learn how to mitigate regulatory risk and improve trial diversity by reducing site burden and leveraging integrated technology to reach U.S. patients in their own communities.

Optimizing The Path From First-In-Human To Proof-Of-Concept

By collapsing the gaps between manufacturing and clinical trials and integrating these functions into a unified system, teams can adjust formulations in real-time and accelerate timelines.

What MDMA Rejection Taught Drug Developers

Psychedelic compounds show real promise for PTSD, but proving it requires solving unblinding, bias, and safety gaps in trial design.

Clinical Research Consulting Services, Simplified

Expert Support for Clinical Research and Research Administration

DECENTRALIZED TRIALS

Closing The Gender Gap In Clinical Trials With Digital Devices

For decades, women have been underrepresented in clinical trials — a gap that’s not just unfortunate but dangerous. Digital devices might be the difference maker, says research physician Anita Phung, MRGCP, MRCP, MBBS, BSc (Hons).

The Pharmacy Advantage In Direct-To-Patient Clinical Supply

Understand state pharmacy regulations, prescription requirements, and operational considerations for shipping clinical supplies directly from pharmacies to patients' homes in decentralized trial models.

Connect With Clinical Leader: